Pretreatment with perfluorohexane vapor attenuates fMLP-induced lung injury in isolated perfused rabbit lungs.
The authors investigated the protective effects and dose dependency of perfluorohexane (PFH) vapor on leukocyte-mediated lung injury in isolated, perfused, and ventilated rabbit lungs. Lungs received either 18 vol.% (n = 7), 9 vol.% (n = 7), or 4.5 vol.% (n = 7) PFH. Fifteen minutes after beginning of PFH application, lung injury was induced with formyl-Met-Leu-Phe (fMLP). Control lungs (n = 7) received fMLP only. In addition 5 lungs (PFH-sham) remained uninjured receiving 18 vol.% PFH only. Pulmonary artery pressure (mPAP), peak inspiratory pressure (P(max)), and lung weight were monitored for 90 minutes. Perfusate samples were taken at regular intervals for analysis and representative lungs were fixed for histological analysis. In the control, fMLP application led to a significant increase of mPAP, P(max), lung weight, and lipid mediators. Pretreatment with PFH attenuated the rise in these parameters. This was accompanied by preservation of the structural integrity of the alveolar architecture and air-blood barrier. In uninjured lungs, mPAP, P(max), lung weight, and lipid mediator formation remained uneffected in the presence of PFH. The authors concluded that pretreatment with PFH vapor leads to an attenuation of leukocyte-mediated lung injury. Vaporization of perfluorocarbons (PFCs) offers new therapeutic options, making use of their protective and anti-inflammatory properties in prophylaxis or in early treatment of acute lung injury.
Bleyl
Jörg U
JU
Clinic for Anaesthesiology and Intensive Care Therapy, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. joerg.bleyl@uniklinikum-dresden.de
Heller
Axel R
AR
Fehrenbach
Antonia
A
Heintz
Manuel
M
Fehrenbach
Heinz
H
Klenz
Gesa
G
Gama de Abreu
Marcelo
M
Hübler
Matthias
M
Spieth
Peter M
PM
Koch
Thea
T
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D019610:Cytoprotection; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005466:Fluorocarbons / Q000494:pharmacology*; D066298:In Vitro Techniques; D018836:Inflammation Mediators / Q000378:metabolism; D001239:Inhalation / Q000187:drug effects; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology; D008168:Lung / Q000098:blood supply / Q000187:drug effects* / Q000276:immunology / Q000473:pathology / Q000503:physiopathology; D055370:Lung Injury / Q000139:chemically induced / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D009240:N-Formylmethionine Leucyl-Phenylalanine; D009929:Organ Size / Q000187:drug effects; D010477:Perfusion; D011651:Pulmonary Artery / Q000187:drug effects / Q000503:physiopathology; D011654:Pulmonary Edema / Q000139:chemically induced / Q000517:prevention & control; D011817:Rabbits; D013997:Time Factors; D014835:Volatilization
D000893:Anti-Inflammatory Agents; D005466:Fluorocarbons; D018836:Inflammation Mediators; D009240:N-Formylmethionine Leucyl-Phenylalanine; C078626:perflexane